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Abstract
Notch plays a protumorigenic role in many cancers including prostate cancer
(PCa). Global notch inhibition of multiple Notch family members using
γ‐secretase inhibitors has shown efficacy in suppressing PCa growth in murine
models. However, global Notch inhibition is associated with marked toxicity
due to the widespread function of many different Notch family members in
normal cell physiology. Accordingly, in the current study, we explored if
specific inhibition of Notch1 would effectively inhibit PCa growth in a murine
model. The androgen‐dependent VCaP and androgen‐independent DU145 cell
lines were injected subcutaneously into mice. The mice were treated with either
control antibody 1B7.11, anti‐Notch1 antibody (OMP‐A2G1), docetaxel or the
combination of OMP‐A2G1 and docetaxel. Tumor growth was measured using
calipers. At the end of the study, tumors were assessed for proliferative
response, apoptotic response, Notch target gene expression, and DNA damage
response (DDR) expression. OMP‐A2G1 alone inhibited tumor growth of both
PCa cell lines to a greater extent than docetaxel alone. There was no additive or
synergistic effect of OMP‐A2G1 and docetaxel. The primary toxicity was weight
loss that was controlled with dietary supplementation. Proliferation and
apoptosis were affected differentially in the two cell lines. OMP‐A2G1 increased
expression of the DDR gene GADD45α in VCaP cells but downregulated
GADD45α in Du145 cells. Taken together, these data show that Notch1
inhibition decreases PCa xenograft growth but does so through different
mechanisms in the androgen‐dependent VCaP cell line vs the androgen‐
independent DU145 cell line. These results provide a rationale for further
exploration of targeted Notch inhibition for therapy of PCa.
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1 | INTRODUCTION
Notch is an evolutionarily conserved pathway with roles
in various cellular processes including proliferation,
apoptosis, migration, growth, and differentiation. Notch
signaling is mediated by four receptors (Notch 1‐4) and
five ligands (delta‐like 1, 3, and 4 & jagged 1 and 2).1 The
transmembrane surface receptors (Notch1‐4) on one cell
interact with membrane‐bound ligands expressed on the
surface of an adjacent cell. Through a series of proteolytic
events mediated by γ‐secretase, the Notch intracellular
domain (NICD) is released from the interior cell
membrane into the cytoplasm and translocates into the
nucleus, where it participates in a core transcriptional
complex that turns on target genes. Notch signaling is
deregulated during initiation and progression of prostate
cancer (PCa).2
PCa is the most common cancer of men. Proliferation,
maintenance, and function of prostate cells is regulated
by a number of signaling pathways, including Notch,
DNA damage response (DDR) and the androgen receptor
(AR). In both clinical samples and in cell culture,
multiplicity in AR, Notch, and DDR activity has been
shown to impact PCa biology and therapy response. It
has been demonstrated that the androgen‐signaling
pathway and Notch pathway can regulate each other in
PCa. Yu et al3 showed that in PCa patients, jagged 1
expression correlates with cancer progression in a process
mediated through AR overexpression. Another study
reported that Hey1, a transcription factor activated by
Notch1, repressed AR‐dependent transcriptional
activity.4 However, this repression is absent in PCa
tumors, due to exclusion of Hey1 from the nucleus in
tumor cells, suggesting that progression to aggressive AR‐
independent PCa could in part be due to nuclear
exclusion of repressors.4 Therefore, further understand-
ing the interplay between AR and Notch signaling in PCa
may uncover additional mechanisms through which
Notch contributes to PCa progression.
Previously, we explored the impact of global Notch
inhibition using a γ‐secretase inhibitor (GSI) on two PCa
hormone insensitive cell lines (PC3 and Du145). The GSI
induced a combination of decreased proliferation, in-
duced apoptosis, and blocked tumor angiogenesis.5 There
are several drawbacks to use of global Notch inhibition
including marked toxicity and targeting multiple Notch
receptors as opposed to those specifically shown to be
oncogenic. This is of particular therapeutic relevance as
Notch can function either as a tumor‐suppressive or an
oncogenic mediator in PCa.6 Hence, targeting specific
Notch pathway molecules that have protumor‐promoting
activity, while sparing Notch pathway molecules that
have antitumor activity may provide a therapeutic
benefit. Therefore, in this study, we investigated the
therapeutic efficacy of anti‐Notch1 monoclonal antibody
on both hormone‐independent and ‐dependent PCa
xenografts.
2 | MATERIALS AND METHODS
2.1 | Antibodies
OMP‐A2G1 (anti‐Notch1) and the control antibody 1B7.11
(against dinitrophenol) monoclonal antibody were provided
by OncoMed Pharmaceuticals (Redwood City, CA).
2.2 | Cell lines and cell culture
condition
Human prostate cancer cell lines Du145 was obtained
from the American Type Culture Collection (Rockville,
MD) and cultured in Rosewell Park Memorial Institute
1640 medium (Invitrogen Co, Carlsbad, CA) supplemen-
ted with 10% fetal bovine serum (FBS) and 1% penicillin‐
streptomycin (Life Technologies, Carlsbad, CA).7,8 VCaP
cells (kindly provided by Dr. Kenneth Pienta, University of
Michigan, Ann Arbor, MI) were maintained in Dulbecco's
modified Eagle's medium (Life Technologies, Inc).9
with 10% FBS and 1% penicillin‐streptomycin (Life
Technologies). All cultures were maintained at 37°C, 5%
CO2, and 100% humidity. Cell identification is completed
semiannually using polymerase chain reaction (PCR) for
short tandem repeats.
2.3 | Cell growth assay
Du145 and VCaP cells were grown in 96‐well plates. Cells
were then treated with either GSI(R04), OMP‐A2G1 (0.1,
1, 10, and 100 μg/mL) or vehicle for 72 hours. Cell
proliferation reagent WST‐1 was added and incubated at
37°C and 5% CO2 for 4 hours. Absorbance was then
measured at 440 nm with a SpectraMax M5 plate reader.
Data are presented as mean ± SD from triplicate deter-
minations.
2.4 | Animal studies
Six to seven‐week‐old, male CB17/Icr‐Prkdcscid/IcrIcoCrl
(SCID) mice (Charles River, Wilmington, MA) were housed
under pathogen‐free conditions. All experimental protocols
were approved by the University of Michigan Animal Care
and Use Committee. For subcutaneous injection, 1 × 106 of
Du145 cells and 3 × 106 of VCaP cells were injected
subcutaneously into the flank. When cohorts of tumors
reached 100 to 200mm3, mice were randomly assigned to
control and three treatment groups (13‐15 mice per group):
AHMED ET AL. | 16947
(1) Control antibody 1B7.11 (against dinitrophenol; (2)
OMP‐A2G1 (5mg/kg weekly); (3) control antibody plus
docetaxel (5mg/kg weekly); (4) OMP‐A2G1 plus docetaxel
(same dosage as above). Tumor size and body weight were
measured twice a week. Tumor volume was calculated
following the formula: tumor volume V= a× b2 × 0.52,
where a is the length of the tumor and b is the width of the
tumor.5
2.5 | Western blot analysis
Du145 and VCaP subcutaneous xenografts were har-
vested after treatment and stored at −80°C. Tumor
tissues were homogenized in ice‐cold radioimmunopre-
cipitation assay lysis buffer (Millipore, Billerica, MA)
containing protease inhibitors and phosphatase inhibi-
tors. The protein concentration of tumor extracts was
determined using the Peirce BCA Protein Assay Kit
(ThermoFisher, Waltham, MA). Target protein expres-
sion was analyzed using Western blot analysis, with
β‐tubulin/glyceraldehyde 3‐phosphate dehydrogenase
(GAPDH) used as loading controls. Notch1, NICD,
GADD45α, and p53 were obtained from Cell Signaling
Technology Company (Beverly, MA); β‐tubulin and
GAPDH were obtained from Sigma‐Aldrich (St Louis,
MO). The antibodies were diluted as recommended by
the manufacturers.
2.6 | Quantitative real‐time PCR
Total RNA was extracted from Du145 and VCaP sub-
cutaneous xenografts using RNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer's protocol.
Using the Superscript III first‐strand synthesis system
(Invitrogen, Inc), messenger RNA (mRNA) was reverse‐
transcribed into complementary DNA (cDNA). SYBR green
(Qiagen) was used to amplify cDNA using quantitative real‐
time reverse transcriptase polymerase chain reaction (qRT‐
PCR). Relative quantification was done using the ΔΔCt
method, normalizing to GAPDH mRNA.
2.7 | Immunohistochemistry
Subcutaneous tumors were fixed in 10% formalin.
Five‐micron (5 μM) sections were used for hematoxylin‐
eosin and immunohistochemistry. Ki67 (1:500; Santa
Cruz Biotechnology, Dallas, TX) and cleaved caspase‐3
(1:300; Cell Signaling Technology, Danvers, MA) were
stained as per the manufacturer's protocols. Sections
were examined for positive staining and quantified as
previously described.5 Representative fields were photo-
graphed under ×40 magnification.
2.8 | Statistical analysis
Numerical data are expressed as mean ± SD. Statistical
analysis was performed by one‐way analysis of variance
for multiple comparisons and the Student t test for an
independent analysis. Differences with P< 0.05 were
determined as statistically significant.
3 | RESULTS
3.1 | Anti‐Notch1 antibody decreases
proliferation of hormone‐sensitive
prostate cancer cells
We first explored baseline gene expression levels of the
Notch ligands, receptors, and Notch pathway activation
in several prostate cancer cells. Initially, RT‐PCR analysis
was performed revealing a varied expression of among
the PCa cell lines. Downstream target genes of the Notch
pathway were higher in VCaP compared to the other two
cell lines (Figure 1A). In terms of protein expression,
Notch1 was highest in DU145 and lowest in VCaP;
whereas, it was expressed at various levels among the
other prostate cancer cell lines (Figure 1B). These results
confirm previous work that VCaP cells express Notch1
protein10 as did DU145 cells.11-13 We next explored if
Notch1 inhibition impacted the growth of the PCa cells
lines. First, we treated cells with the GSI R04 for 72 hours
to determine the impact of global Notch inhibition on
these cells. R04 inhibited overall cell growth of both cell
lines in a dose‐responsive fashion (Figure 1C). We next
determined the impact of specific inhibition of Notch1 on
prostate cancer cell growth. Accordingly, we cultured the
prostate cancer cells with increasing doses of anti‐Notch1
monoclonal antibody OMP‐A2G1 for 72 hours. OMP‐
A2G1 reduced cell growth of both cell lines in a dose‐
responsive fashion with more of an inhibitory impact
VCaP compared to DU145 (Figure 1D). The response in
VCaP with low Notch1 expression compared to Du145
supports the efficacy of OMP‐A2G1. These results
indicate that Notch1 can promote the growth of both
androgen‐sensitive and insensitive PCa cells.
3.2 | Notch1 inhibits the growth of both
hormone‐dependent and ‐independent
xenografts
To investigate the potential therapeutic efficacy of
OMP‐A2G1 in vivo, we subcutaneously injected VCaP
and Du145 into mice and allowed tumors to become
established to a volume range of 100 to 200mm3. At this
point, mice were randomized into four treatment
groups consisting of control antibody 1B7.11 (against
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dinitrophenol), control antibody plus docetaxel, OMP‐
A2G1 alone, or OMP‐A2G1 plus docetaxel and treated as
indicated in Figure 2A over a 6‐week period. Docetaxel
inhibited the growth of VCaP xenografts compared to
the control group (Figure 2B). OMP‐A2G1 inhibited the
growth of VCaP xenografts to a greater extent than
docetaxel alone did. The combination of docetaxel and
OMP‐A2G1 had an inhibitory effect similar to that of
OMP‐A2G1 alone indicating that there was no additive
or synergistic effect for these two compounds. These
growth effects are reflected in the final tumor weights
of all four groups of VCaP xenografts (Figure 2B).
OMP‐A2G1 had a similar impact on the Du145
xenografts with OMP‐A2G1 inhibiting tumor growth
more than docetaxel (Figure 2C). Taken together,
these results indicate that OMP‐A2G1 has a strong
antitumor effect; however, there was no additive or
synergistic activity between docetaxel and OMP‐A2G1.
OMP‐A2G1 primary toxicity was weight loss, which
was controlled with dietary supplementation.
3.3 | Anti‐Notch1 exerts mixed effects
To determine if Notch1 inhibition mediates its antitumor
effect through modulating proliferation and/or apoptosis
in vivo, we assessed the expression of Ki67 (proliferation
marker) and cleaved caspase‐3 (apoptosis marker) in the
VCaP and DU145 xenografts. None of the solitary or
combination treatments had an impact on the number of
cells expressing Ki67 in the VCaP xenografts (Figure 3A).
In contrast, OMP‐A2G1 and docetaxel alone increased
the number of cleaved caspase‐3 positive cells; however,
the combination of OMP‐A2G1 and docetaxel had no
impact on the number of cleaved caspase‐3 positive cells.
In VCaP xenograft, OMP‐A2G1 and docetaxel alone
had no impact on the number of cells expressing
Ki67; although, the combination of both decreased the
proportion of Ki67 positive cells in the Du145 xenografts
(Figure 3B). Furthermore, none of the individual or
combination treatments had an impact on the number of
cells expressing caspase‐3.
FIGURE 1 Notch signaling evaluation in hormone‐dependent and ‐independent prostate cancer cell lines. A, To measure mRNA, total
RNA was extracted from three different prostate cancer cell lines (LNCaP, DU145, and VCaP) and 1 μg of total RNA was reverse‐transcribed
and subjected to qRT‐PCR for the indicated target gene and normalized to GAPDH and then reported relative to VCaP. B, To measure
protein, indicated cell lines were subjected to immunoblot for anti‐Notch1 antibody. β‐Tubulin was used as a loading control. C, 3 × 103
DU145 and VCaP cells were treated with GSI R04 for 72 hours. Cell viability was measured using resazurin cell viability assays. D, 3 × 103
DU145 and VCaP cells were treated with OMP‐A2G1 (0‐80 μg/mL) 72 hours. Cell viability was measured using resazurin cell viability
assays. GAPDH, glyceraldehyde 3‐phosphate dehydrogenase; mRNA, messenger RNA; qRT‐PCR, quantitative real‐time reverse transcriptase
polymerase chain reaction. *P< 0.05 and **P< 0.01
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3.4 | The response of Notch target genes
to Notch1 varies in xenografts
To determine the effect of Notch1 inhibition on Notch
pathway‐related genes in the tumor tissues, we subjected
the VCaP and Du145 xenografts to Western blot analysis.
In response to OMP‐A2G1 antibody alone, VCaP
xenografts did not show a decrease of NICD protein
expression (Figure 4A); whereas, the Notch target,
Hes1 mRNA expression was significantly decreased
(Figure 4C). In contrast in DU145, the OMP‐A2G1
antibody alone decreased NICD protein expression, but
not Hes1 mRNA expression (Figure 4B,D). The combina-
tion of docetaxel and OMP‐A2G1 did significantly
decrease Hes1 mRNA expression in Du145 xenografts
(Figure 4D). We looked at additional Notch1 targets such
as Hes6, Hey1, and Notch3. In VCaP xenografts, OMP‐
A2G1 treatment led to a downregulation trend in these
transcripts; whereas, there was no impact on them in
DU145 cells (data not shown). Taken together, these
results indicate that OMP‐A2G1 antibody impacts
Notch1‐mediated signaling in these PCa cells and this
might be by different mechanisms.
FIGURE 2 OMP‐A2G1 had a significant antitumor effect in VCaP and Du145 xenografts. A, General scheme for OMP‐A2G1 and
docetaxel treatment. B,C, Du145 (1 × 106) and VCaP (3 × 106) were injected subcutaneously into mice. When cohorts of tumors reached 100
to 200mm2 mice were divided into four treatment groups consisting of control antibody 1B7.11 (against dinitrophenol), control antibody
plus docetaxel, OMP‐A2G1 alone, or OMP‐A2G1 plus docetaxel and treated with as described in Section 2 (N= 12‐14 mice per group). D, At
the end of the study, tumors were harvested and weighted, mean weights were then graphed. NS, no significant difference. *P< 0.05,
**P< 0.001, and ***P< 0.0001
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3.5 | Intrinsic PCa cell line properties
influence response to Notch1 inhibition
We next explored why the two different PCa cell lines
demonstrated differential responses to OMP‐A2G1
therapy. Notch signaling is involved in a wide range
of cellular processes and any one of these can be altered
depending on the state of the cell. We focused on the
underlying differences between our models. VCaP is AR
and ERG positive with a functional mutated p53 protein
while DU145 is both AR and ERG negative with a
nonfunctional p53 possible.15 Mohamed et al14 reported
synergy between Notch and AR inhibition in VCaP but
not DU145. VCaP cells had decreased cell growth, cell
survival, and enhanced apoptosis in response to Notch
and the AR inhibitor bicalutamide while no change was
observed in AR‐negative DU145 cells.14 DU145 showed
no change in protein expression after treatment with
Notch and AR inhibitors. Another inherent difference
is the p53 status of VCaP and DU145. DU145 harbors
mutant Leu‐223 and Phe‐274 that renders p53 non-
functional, while VCaP (mutant p53, Trp‐248) has been
shown to have a functional p53 protein.15,16 Carroll
et al15 showed that DDR in PCa cell lines was
dependent on p53 status and that alteration of this
pathway is vital in the survival of advanced PCa cells
during exposure to anticancer therapies, specifically
agents that induce DNA damage. Since DDR is
dependent on p53 functional status, which is different
between VCaP and DU145 cells, we evaluated the effect
of OMP‐A2G1 on DDR. To perform this, we utilized an
array consisting of genes involved in Ataxia telangiec-
tasia‐mutated and RAD3‐related (ATM/ATR) signaling,
DDR, apoptosis, and cell cycle. Equal amounts of RNA
from each xenograft was characterized for the same 84
genes involved in DNA damage signaling pathways.
VCaP tumors treated with OMP‐A2G1 had dysregula-
tion of genes involved in cell cycle and apoptosis
(Figure 5A). In contrast, DU145 did not show any
dysregulated genes in common with VCaP but had
dysregulation in several DDR genes (Figure 5B).
Although the dysregulated genes were different among
VCaP and DU145 cells, they have a p53 pathway in
FIGURE 3 : OMP‐A2G1 induces apoptosis alone and in combination with docetaxel in DU145 and suppresses tumor cell proliferation
in VCaP. A,B, At the end of the study, tumors were harvested from the mice as described in methods. A portion of the DU145 and VCaP
tumor xenografts (n= 5) were subjected to immunohistochemistry for proliferation (anti‐Ki67) and apoptosis (anticleaved caspase‐3).
Left: Representative photomicrographs of Ki67 and cleaved caspase‐3 stained tumor sections (×40 magnification). Right: Quantitation of
Ki67 and cleaved caspase‐3 positive percentage. *P< 0.05 and **P< 0.01
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FIGURE 4 Differential Notch signaling response to OMP‐A2G1 treatment. A,B, Total protein was isolated from OMP‐A2G1 and
control‐treated DU145 and VCaP and subject to immunoblot for NICD1 as described in Figure 1. GAPDH was used as a loading control.
Bands were measured using densitometry and values first normalized to respective GAPDH bands. C,D, To measure mRNA, total RNA was
extracted from OMP‐A2G1 and control‐treated DU145 and VCaP. Total RNA (1 μg) was subjected to qRT‐PCR using primers for Hes1 and
GAPDH (as a loading control). GAPDH, glyceraldehyde 3‐phosphate dehydrogenase; mRNA, messenger RNA; NICD1, Notch intracellular
domain; qRT‐PCR, quantitative real‐time reverse transcriptase polymerase chain reaction. *P< 0.05 and **P< 0.01
FIGURE 5 OMP‐A2G1‐treated VCaP and Du145 xenografts have differential DNA damage response. A, Four hundred nanograms of
total RNA was extracted from DU145 and VCaP‐treated tumors and their respective control antibody‐treated tumors and was reverse‐
transcribed and subjected to qRT‐PCR using the human DNA damage signaling pathway PCR array. Ct values were analyzed using the
GeneGlobe Data Analysis Center, relative gene expression between of top genes in each xenograft was then plotted. B,C, Total protein was
isolated from OMP‐A2G1 and control‐treated DU145 and VCaP and subject to immunoblot for p53 and GADD45α as described in Figure 1.
GAPDH and β‐tubulin were used as a loading control. GAPDH, glyceraldehyde 3‐phosphate dehydrogenase; qRT‐PCR, quantitative
real‐time reverse transcriptase polymerase chain reaction
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common. Notch signaling has been shown to regulate
p53 expression via both Hey1 and Hes117 as well as
DDR.18 Accordingly, we explored for an impact of
Notch1 inhibition on p53 and Gadd45α, which is a
downstream target of p53 in DDR. In VCaP xenografts,
OMP‐A2G1 downregulated p53 expression (Figure 5B).
This was associated with an increase in downstream
target Gadd45α. In contrast, in DU145 cells, which lack
a functional p53, OMP‐A2G1 had no impact on p53
expression but did decrease Gadd45α (Figure 5C).
These results suggest that p53 function could contribute
to a differential impact of Notch1 inhibition in PCa
cells.
4 | DISCUSSION
Notch signaling is multifaceted and is known to
associate with multiple processes including p53 and
androgen‐signaling pathways. In our study, we eval-
uated the response to OMP‐A2G1 in androgen‐depen-
dent and independent cells. OMP‐A2G1 reduced the
growth of both DU145 and VCaP xenografts. The
overall impact of OMP‐A2G1 on cellular mechanisms
(ie, decreased proliferation or increased apoptosis)
accounting for the decreased tumor growth appeared
different between the DU145 and VCaP xenografts.
Specifically, while VCaP showed a significant upregu-
lation in cleaved caspase‐3, DU145 xenografts showed
no difference between treatment groups. Both cell lines
have inherent differences not only in AR but ERG and
p53 expression, which may account for the differential
response. Canonical and noncanonical Notch are
known to crosstalk with AR and p53.16 Considering
all of these, we took a closer look at p53 and DDR and
showed differences in response between the xenografts
exposed to OMP‐A2G1. Gadd45α, a proapoptotic and
p53‐dependent DDR protein was upregulated in VCaP
xenografts in response to OMP‐A2G1. Recent work has
attributed GADD45α upregulation to VCaP expression
of fusion protein TMPRSS2‐ERG.22 DU145 cells express
mutant nonfunctional p53 that causes a defective G1
checkpoint16 which can account for the lack of
Gadd45α upregulation upon OMP‐A2G1 treatment.
These results are supportive of the possibility that
DNA damage‐induced p53 contributes to the increased
apoptosis seen in VCaP when Notch1 is inhibited. Loss
of p53 function can relieve apoptosis and lead to
growth advantage.23 It's been reported in multiple
cancers that p53 loss is synergistic with Notch1
expression.
Given that Notch1 has a spectrum of activities, our
data suggest that Notch1 inhibition can impede PCa
growth through various mechanisms such as DDR, AR,
and p53 signaling. Recent work on Notch signaling and
DDR shows that Notch1 can displace key DDR proteins
and alter the response to damage.18 The crosstalk
between AR and Notch1 is also crucial in the response
to Notch inhibition. Downstream targets of Notch
signaling Hey1, Hey2, and HeyL were shown to repress
AR signaling.4,29 Our data show an upregulation of AR
in anti‐Notch1 treated VCaP tumors (data not shown).
Mohamed et al,14 showed that Notch1 and Notch2 have
ERG binding sites upstream of promoters in the
TMPRSS2‐ERG positive VCaP but not DU145. They
also show that dual AR and Notch inhibition repressed
proliferation and increased apoptosis in VCaP but not
DU145. Kron et al30 recently showed that TMPRSS2‐
ERG fusion activates Notch signaling in primary PCa.
Furthermore, Notch inhibition was shown to overcome
resistance to androgen deprivation in PCa cells,
strengthening the link between Notch and AR
signaling.31
VCaP AR expression may explain the lack of
difference in proliferation of OMP‐A2G1‐treated tumors.
Another possibility is the ERG expression present in
VCaP but not DU145. Mohamed et al14 showed that AR
and Notch inhibition delivered a significant increase in
apoptotic cells and a decrease in cell growth and cell
survival in VCaP, while DU145 showed no difference.
In summary, our study demonstrates that specific Notch1
inhibition reduces PCa xenograft growth. The data indicates
the antitumor effects may be associated with DDR and AR
status. These results suggest that further exploration of
targeted Notch inhibition in combination with DNA‐
damaging agents and AR inhibitors may lead to promising
PCa therapies.
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